July 17, 2025

Vapes Outperform Nicotine Replacement Therapy in Cessation Trial

Researchers found vaporized nicotine products more effective than nicotine replacement therapy for smoking cessation among socioeconomically disadvantaged adults.

Conexiant

July 17, 2025

Nirsevimab Shows 83% Efficacy Over 6 Months

A large clinical trial in Europe showed that a single dose of nirsevimab reduced infant hospitalizations for RSV-associated lower respiratory tract infections by over 80% over a six-month period.

Conexiant

July 17, 2025

Cancer History Linked to Severe COVID-19, Study 

Adult childhood cancer survivors had a higher risk of severe COVID-19 despite lower infection rates and higher vaccination coverage.

Conexiant

July 11, 2025

Small Air Pollution Increases Linked to Fibrosis

A large imaging study found that even small increases in long-term exposure to fine particulate air pollution were linked to higher levels of myocardial fibrosis, a known marker of adverse heart remodeling, in both healthy individuals and patients with dilated cardiomyopathy.

Conexiant

July 10, 2025

Apheresis Shows Promise for Removing Microplastics From Human Blood

Extracorporeal therapeutic apheresis demonstrated the ability to remove microplastic-like particles from human blood in patients with myalgic encephalomyelitis/chronic fatigue syndrome, according to a study published in Brain Medicine.

Conexiant

July 09, 2025

Medical Oddities: Mondays May Mess With Hormones

Monday cortisol, THC slip-ups, rewiring retinas, tea-buffed muscles, and psyche gyms are what’s the buzz this week!

Conexiant

July 09, 2025

Recombinant Zoster Vaccine Linked to New-Onset Lupus

Researchers report the first documented case of systemic lupus erythematosus following Shingrix vaccination.

Conexiant

July 07, 2025

FDA Approves First Oral Hereditary Angioedema Treatment

FDA approves Ekterly (sebetralstat), the first oral on-demand treatment for hereditary angioedema, shown in trials to provide faster symptom relief and eliminate the need for injection.

Conexiant

July 01, 2025

FDA Approves Low-IgA IG Therapy

GAMMAGARD LIQUID ERC is the first ready-to-use liquid immunoglobulin therapy with IgA ≤2 µg/mL for primary immunodeficiency in individuals aged 2 years and older.

Conexiant